Searching On:

Drug:

Nexavar

View:
Expand Collapse Nexavar  - General Description sorafenib tosylate
The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.
Chemical Name
2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3- trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate tosylate
Drug Code Name
BAY 54-9085
Drug Short Name
SFN
Synonyms
BAY 43-9006
BAY 43-9006 Tosylate Salt
US Brand Names
Nexavar
sorafenib tosylate
The tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.
Chemical Name
2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3- trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate tosylate
Drug Code Name
BAY 54-9085
Drug Short Name
SFN
Synonyms
BAY 43-9006
BAY 43-9006 Tosylate Salt
US Brand Names
Nexavar

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (D) - Drug
Trial Status: Showing all 2 results Per Page:
Protocol # Title Location Status Match
NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer MGH Open D
NCT02303444 An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors MGH Open D
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
Trial Status: Showing all 2 results Per Page:

Share with your Physican

Print information for your Physician.

Print information